Stephen Ubl, the leader of the drug industry’s powerful Washington, DC, lobbying group PhRMA, plans to step down, Endpoints News has learned from sources familiar

Plus, news about Novavax, ReAlta and AtaiBeckley: Merck adjusts China vaccine supply deal: The company and its distribution partner Zhifei have tweaked their agreement as

Gilead Sciences has dedicated around $11 billion so far this year to three acquisitions meant to bolster its pipelines in cancer and immunology. The pharma

Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a “destruction in shareholder value.”

A startup developing a one-time treatment that is intended to rewind the clock on dying cells announced a major influx of funding. Life Biosciences, a